(ASH) Ashland Inc. – Value – Zacks Rank Buy
Ashland Inc. (ASH), the chemical manufacturer, posted a big second quarter surprise as cost cutting helped the bottom line. The company has surprised on estimates 3 out of the last 4 quarters by an...
View Article(ASH) Investing in the Biotech Sector: Here’s An Easy Way to Profit from...
by Marc Lichtenfeld, Healthcare Expert Wednesday, November 11, 2009: Issue #1135 Investing in the biotech sector can be risky – no doubt about that. But you know what? There are a lot of ways to make...
View Article(MITI) Micromet & Bayer Take a BiTE
Micromet (MITI), a biopharmaceutical company, is dependent on many of its collaborating partners for its product portfolio. In this respect, the company received good news with Bayer exercising its...
View Article(CEPH) Cephalon Drug Gains on Positive Data
Cephalon, Inc. (CEPH) oncology product Treanda could see a significant rise in demand thanks to encouraging data presented at the recently conducted annual meeting of the American Society of Hematology...
View Article(AGYS) Company News for June 01, 2011 – Corporate Summary
• Ship builder General Dynamics Corp.’s (NYSE:GD) share prices rose 4.15% to $74.22 after the company after it announced that it would receive an additional $744 million from the Defense Department...
View Article(AFAM) Company News for June 21, 2011 – Corporate Summary
• Manufacturer and distributors of stainless steel and titanium products, Carpenter Technology (NYSE:CRS) has concluded a merger agreement with Latrobe Specialty Metals as per which the former will...
View Article(MITI) Micromet Loss Less Than Analyst Estimates – Revenues Rise
Micromet Inc.’s (MITI) second quarter 2011 loss per share came in at 19 cents (after adjusting for the change in fair value of warrants), wider than the year-ago loss of 15 cents per share (also...
View Article(CE) Celanese Acquires Ashland Assets
Celanese Corporation (CE) entered into an agreement to acquire polyvinyl acetate assets from Ashland Inc. (ASH), including two product lines, Vinac and Flexbond. The transaction is expected to close...
View Article(MITI) Micromet Begins New Trial
Micromet Inc. (MITI) recently announced that it has begun a mid-stage registrational trial of its lead pipeline candidate, blinatumomab, in adult patients with B-precursor relapsed refractory acute...
View Article(MITI) Micromet Analyst Maintains Neutral on Shares
We have maintained a Neutral rating on Micromet, Inc. (MITI) with a target price of $7.00 per share following appraisal of third quarter 2011 results. Micromet’s third quarter 2011 loss per share came...
View Article(DOW) Three More Industries Thriving From Record-Low Natural Gas Prices
by Mike Kapsch, Investment U Research Tuesday, January 24, 2012 Since hitting a high of $15.37 in December 2005, the price of natural gas has plunged to its lowest level in over a decade to $2.30....
View Article(LLY) Eli Lilly and Company GLP-1 Agonist Delivers
Eli Lilly and Company (LLY) recently presented positive phase II data on its type II diabetes candidate, dulaglutide. The company said that dulaglutide met its primary endpoint in the study....
View Article(CRM) Salesforce Beats Estimates in Second Quarter
Salesforce.com Inc. (CRM) reported second quarter fiscal 2013 adjusted earnings per share (EPS) of 5 cents, a penny ahead of the Zacks Consensus Estimate of 4 cents. Despite the marginal beat, shares...
View Article(BAX) Baxter Presents Study Outcome
Baxter International (BAX) recently revealed critical Phase I/III study outcomes analyzing the efficacy and safety of BAX 326. This is an investigational recombinant factor IX protein, which is...
View Article